21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer when recurrence score (RS) was ≥31. HER2 is a component of the RS algorithm with a positive coefficient and contributes to higher RS values. Accrual to B-20 occurred prior to routine testing for HER2, so questions have arisen regarding assay performance if HER2-positive patients were identified and excluded. We report an exploratory reanalysis of the B-20, 21-gene study following exclusion of such patients. Patients were considered HER2 positive if quantitative RT-PCR for HER2 was ≥11.5 units, and excluded from re-analyses performed using the original cutoffs: 25 employed in TAILORx. Genetics: multigene panel predicts chemo benefit regardless of HER2 status A commonly used genetic test helps to predict whether patients with estrogen-receptor positive, node-negative breast cancer stand to gain from chemotherapy. Charles Geyer from NRG Oncology/NSABP and Virginia Commonwealth University and colleagues reanalyzed data from a decades-old study that helped establish a 21-gene panel as a tool for determining whether to add chemotherapy to endocrine therapy for women with estrogen-receptor positive, node-negative breast cancer. The researchers excluded patients with HER2-positive disease because HER2 gene expression is part of the diagnostic test and questions have persisted